Tysabri drives 48% increase in Biogen Idec's fourth-quarter income
This article was originally published in Scrip
Biogen Idec reported total revenues in 2009 of $4.4 billion, an increase of 7% on the previous year, driven primarily by its multiple sclerosis franchise.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.